Browse Subject Areas

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Microstructural white matter alterations in preclinical Alzheimer’s disease detected using free water elimination diffusion tensor imaging

  • Andrew R. Hoy ,

    Affiliations Lieutenant, Medical Service Corp, United States Navy, Falls Church, Virginia, United States of America, Department of Medical Physics, University of Wisconsin, School of Medicine and Public Health, Madison, Wisconsin, United States of America, Waisman Laboratory for Brain Imaging and Behavior, University of Wisconsin, Madison, Wisconsin, United States of America, Department of Radiology and Radiologic Sciences, Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States of America


  • Martina Ly,

    Affiliations Geriatric Research Education and Clinical Center, William S. Middleton Memorial Veteran's Hospital, Madison, Wisconsin, United States of America, Wisconsin Alzheimer's Disease Research Center, University of Wisconsin, Madison, Wisconsin, United States of America, Neuroscience Training Program, University of Wisconsin, Madison, Wisconsin, United States of America

  • Cynthia M. Carlsson,

    Affiliations Geriatric Research Education and Clinical Center, William S. Middleton Memorial Veteran's Hospital, Madison, Wisconsin, United States of America, Wisconsin Alzheimer's Disease Research Center, University of Wisconsin, Madison, Wisconsin, United States of America, Wisconsin Alzheimer’s Institute, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States of America

  • Ozioma C. Okonkwo,

    Affiliations Geriatric Research Education and Clinical Center, William S. Middleton Memorial Veteran's Hospital, Madison, Wisconsin, United States of America, Wisconsin Alzheimer's Disease Research Center, University of Wisconsin, Madison, Wisconsin, United States of America, Wisconsin Alzheimer’s Institute, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States of America

  • Henrik Zetterberg,

    Affiliations Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, UCL Institute of Neurology, Queen Square, London WC1N 3BG, United Kingdom

  • Kaj Blennow,

    Affiliation Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden

  • Mark A. Sager,

    Affiliations Wisconsin Alzheimer's Disease Research Center, University of Wisconsin, Madison, Wisconsin, United States of America, Wisconsin Alzheimer’s Institute, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States of America

  • Sanjay Asthana,

    Affiliations Geriatric Research Education and Clinical Center, William S. Middleton Memorial Veteran's Hospital, Madison, Wisconsin, United States of America, Wisconsin Alzheimer's Disease Research Center, University of Wisconsin, Madison, Wisconsin, United States of America, Wisconsin Alzheimer’s Institute, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States of America

  • Sterling C. Johnson,

    Affiliations Geriatric Research Education and Clinical Center, William S. Middleton Memorial Veteran's Hospital, Madison, Wisconsin, United States of America, Wisconsin Alzheimer's Disease Research Center, University of Wisconsin, Madison, Wisconsin, United States of America, Wisconsin Alzheimer’s Institute, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States of America

  • Andrew L. Alexander,

    Affiliations Department of Medical Physics, University of Wisconsin, School of Medicine and Public Health, Madison, Wisconsin, United States of America, Waisman Laboratory for Brain Imaging and Behavior, University of Wisconsin, Madison, Wisconsin, United States of America, Department of Psychiatry, University of Wisconsin, Madison, Wisconsin, United States of America

  • Barbara B. Bendlin

    Affiliations Geriatric Research Education and Clinical Center, William S. Middleton Memorial Veteran's Hospital, Madison, Wisconsin, United States of America, Wisconsin Alzheimer's Disease Research Center, University of Wisconsin, Madison, Wisconsin, United States of America, Wisconsin Alzheimer’s Institute, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States of America

Microstructural white matter alterations in preclinical Alzheimer’s disease detected using free water elimination diffusion tensor imaging

  • Andrew R. Hoy, 
  • Martina Ly, 
  • Cynthia M. Carlsson, 
  • Ozioma C. Okonkwo, 
  • Henrik Zetterberg, 
  • Kaj Blennow, 
  • Mark A. Sager, 
  • Sanjay Asthana, 
  • Sterling C. Johnson, 
  • Andrew L. Alexander


Brain changes associated with Alzheimer’s disease (AD) begin decades before disease diagnosis. While β-amyloid plaques and neurofibrillary tangles are defining features of AD, neuronal loss and synaptic pathology are closely related to the cognitive dysfunction. Brain imaging methods that are tuned to assess degeneration of myelinated nerve fibers in the brain (collectively called white matter) include diffusion tensor imaging (DTI) and related techniques, and are expected to shed light on disease-related loss of structural connectivity. Participants (N = 70, ages 47–76 years) from the Wisconsin Registry for Alzheimer’s Prevention study underwent DTI and hybrid diffusion imaging to determine a free-water elimination (FWE-DTI) model. The study assessed the extent to which preclinical AD pathology affects brain white matter. Preclinical AD pathology was determined using cerebrospinal fluid (CSF) biomarkers. The sample was enriched for AD risk (APOE ε4 and parental history of AD). AD pathology assessed by CSF analyses was significantly associated with altered microstructure on both DTI and FWE-DTI. Affected regions included frontal, parietal, and especially temporal white matter. The f-value derived from the FWE-DTI model appeared to be the most sensitive to the relationship between the CSF AD biomarkers and microstructural alterations in white matter. These findings suggest that white matter degeneration is an early pathological feature of AD that may have utility both for early disease detection and as outcome measures for clinical trials. More complex models of microstructural diffusion properties including FWE-DTI may provide increased sensitivity to early brain changes associated with AD over standard DTI.


Among the neuropathological characteristics associated with dementia due to Alzheimer’s disease (AD), neuronal loss and synaptic pathology—not β-amyloid plaques or neurofibrillary tangles—appear to be most strongly related to dementia severity and cognitive deficits in AD [15]. Beyond standard volumetric magnetic resonance imaging (MRI), there are few options for gauging cell loss, and sensitive approaches [5]are needed, especially to measure early changes. Diffusion-weighted MRI is an increasingly used technique that is sensitive to the random self-diffusion of water molecules. In an unstructured medium, diffusion characteristics reflect properties of the fluid such as temperature and viscosity. However, in structured media such as brain tissue, the measured signals are instead modulated by the geometry of the tissue microstructure [6]. Thus, water molecules are used as a noninvasive endogenous tracer to probe tissue microstructure.

Diffusion tensor imaging (DTI) describes the distribution of diffusion displacements using a Gaussian model and has been used extensively to assess tissue microstructure changes in aging, AD and preclinical AD [712]. Despite the promising sensitivity of DTI, it has known limitations that can impair utility and specific interpretation. To date, very few studies have applied advanced diffusion-weighted imaging methods for characterizing complex microstructural changes in the early stages of AD.

In this study, a free water elimination model was utilized to estimate and remove the signal contributions from cerebrospinal fluid and apparent free water components from the estimated diffusion tensor of the tissue. The FWE-DTI model contains an isotropic diffusion (free water) component with a diffusion coefficient that is constrained to be approximately three times larger than is typically encountered in tissue [13] in addition to the standard diffusion tensor. The free water diffusivity (3x10-3 mm2/s) matches the theoretical diffusion coefficient of CSF at body temperature [14]. The free water signal fraction, denoted as the f-value, corresponds to the water that has minimal interaction with tissue barriers over the diffusion time of the experiment. This model minimizes the CSF contamination of DTI measurements in tissues adjacent to CSF filled spaces such as the ventricles and cerebral cortex [15], which is particularly important as brain atrophy increases with aging and disease burden. Non-zero f-values present in tissues distal from CSF may also reflect the relative volume of extracellular spaces in the tissue [13,16,17].

We hypothesize that FWE-DTI would provide improved sensitivity to microstructural alterations that occur early in the development of AD. In addition to shedding light on the early features of AD pathogenesis, focusing on microstructural alterations is important given that plaques and tangles—while central features of AD—may be accompanied by additional features that predict progression to dementia [4,18,19]. Greater sensitivity in detecting microstructural pathology may help identify individuals at greatest risk for cognitive decline, as well as providing a novel outcome measure for clinical trials.

Thus, this study focused on individuals who may harbor preclinical pathology. Asymptomatic participants were recruited from the Wisconsin Registry for Alzheimer’s Prevention (WRAP) study[20], a cohort that is enriched for AD risk based on parental history of AD and a greater percentage of adults who carry a risk gene for AD, the ε4 allele of apolipoprotein E (APOE ε4)[21]. In addition to standard DTI participants underwent both hybrid diffusion imaging (HYDI) MRI [22] and lumbar puncture to assess levels of proteins related to AD and neurodegeneration in CSF. Biomarkers in CSF were used as a proxy for elevated preclinical AD pathology. CSF Aβ42 was used as a marker of cortical amyloid deposition; CSF Aβ42 predicts conversion to AD dementia [23] and correlates with in vivo [24] amyloid burden measured with positron emission tomography. Phosphorylated tau (P-tau181) was used as a marker of neurofibrillary tangle load [25], and total tau (T-tau) as a marker of degeneration of thin unmyelinated axons. Both P-Tau and T-Tau are elevated in patients with dementia due to AD [26,27], P-tau181 discriminates AD from non-AD dementias [28] and higher levels of T-Tau are associated with a more rapid disease progression [29]. Neurofilament light chain protein (NFL) measured in CSF was used as a marker of large caliber axon degeneration [30], while YKL-40 and monocyte chemoattractant protein 1 (MCP-1) were used as markers of microglial activation and neuroinflammation [31]. Finally, we evaluated soluble amyloid precursor protein beta (sAPPβ) as a marker of upstream APP processing in the β-secretase pathway [32]. We hypothesized that individuals with higher burden of preclinical AD pathology as shown by the CSF biomarkers would show microstructural alterations as measured by FWE-DTI.



Participants were 70 late-middle-aged adults (19 males and 51 females, age: 61.2 ± 6.2 yrs.) without dementia from the WRAP study. The WRAP cohort comprises well characterized and longitudinally followed participants who are either positive or negative for parental history of AD. Positive parental family history of AD classification was defined as having one or both parents with AD as determined by a validated interview [33] or autopsy-confirmed or clinically diagnosed probable AD as outlined by research criteria [34,35], and reviewed by a multidisciplinary diagnostic consensus panel. Detailed medical history obtained from phone interviews were conducted to confirm AD negative participants. Absence of family history of AD required that the participant’s father survive to at least age 70 years and the mother to age 75 years without diagnosis of dementia or cognitive deterioration. APOE ε4 genetic testing was performed at the Wisconsin Alzheimer’s Disease Research Center. Of those recruited 52 were identified as having a positive family history (FH+). Additionally, 27 subjects were carriers of one or more APOE ε4 alleles (APOE4+).

Participants underwent a comprehensive neuropsychological battery that included the Mini Mental State Exam [36]as a general cognitive screen, Rey Auditory Verbal Learning Test (RAVLT)[37], and the Weschler Memory Scale-Revised (WMS-R) [38]to assess memory function, in addition to Trail Making Test A and B [39], which reflect processing speed and executive function, respectively.

Study procedures were approved by the University of Wisconsin Health Sciences institutional review board and were in accordance with U.S. federal regulations. All participants provided written informed consent.

Cerebrospinal fluid analyses

CSF was collected with a Sprotte 25-or 24-gauge spinal needle at the L3/4 or L4/5 using gentle extraction into polypropylene syringes. Samples were collected in the morning after a 12h fast. Approximately 22mL of CSF were combined, gently mixed and centrifuged at 2000g for 10 minutes. Supernatants were frozen in 0.5mL aliquots in polypropylene tubes and stored at -80°C. Samples were analyzed for T-tau, P-tau181 and the 42 amino acid form of amyloid β (Aβ42) using INNOTEST enzyme-linked immunosorbent assays (Fujiurebio, Ghent Belgium). Soluble α- and β-cleaved amyloid precursor protein (sAPPα and sAPPβ, respectively) and MCP-1 levels in CSF were measured using the Meso Scale Discovery technique (Meso Scale Discovery, Gaithersburg, MD, USA). YKL-40 was determined using a sandwich enzyme-linked immunosorbent assay (ELISA) (R&D Systems, Minneapolis, Minn., USA). CSF NFL was measured with a sandwich ELISA method (NF-light ELISA kit, UmanDiagnostics AB, Umeå, Sweden). Board-certified laboratory technicians who were blinded to clinical diagnosis performed all analyses on one occasion. All samples were analyzed according to protocols approved by the Swedish Board of Accreditation and Conformity Assessment (SWEDAC) using one batch of reagents (intra-assay coefficients of variation <10%). Individual biomarkers as well as biomarker ratios were entered into the statistical analyses as predictor variables.

Magnetic resonance imaging


Diffusion-weighted imaging was completed on a 3-Tesla MR750 Discovery scanner (General Electric Healthcare, Waukesha, WI) using an 8-channel receive-only head coil. Separate diffusion scans were acquired for the DTI and FWE-DTI model fits. For the FWE-DTI scan, multiple nonzero b-values were acquired [40]: (number of images x b-value s/mm2): 7 x 0, 6 x 300, 21 x 1200, and 24 x 2700 s/mm2. For the DTI scan, 8 non-diffusion weighted volumes were acquired along with 40 diffusion encoding directions at a b-value of 1000 s/mm2 were acquired. Other pertinent parameters were: TR = 6500 ms (FWE-DTI) or 8000 ms (DTI), TE = 102 ms (FWE-DTI) or 67.8 ms (DTI), slice orientation: axial, slice thickness = 3 mm, and in-plane resolution = 2.5 mm x 2.5 mm interpolated to 0.9735 mm x 0.9735 mm.

MRI processing and analysis.

Image analyses of both DTI and FWE-DTI used both region-of-interest (ROI) and voxel-wise methods. ROIs were generated using tractography methods. The primary outcome measures for DTI were fractional anisotropy (FA), a measure of directional water diffusion that is highly sensitive to microstructural features including axonal density, diameter, and myelination, and mean diffusivity (MD), a measure of isotropic diffusion that is sensitive to cellular structure, necrosis, and edema [6,41]. These were compared to FA and MD generated using FWE-DTI. Additionally, we conducted analyses on f-value generated with FWE-DTI, further described below. The processing steps for all data sets included movement and eddy current correction, gradient direction correction, and brain extraction before fitting the respective models. Eddy current correction and brain extraction was performed using the FSL toolkit.


The FWE-DTI signal model [42] is described by (1) where Si and S0 are the signal from the i-th diffusion and non-diffusion weighted measurements, respectively, Diso = 3 x10-3mm2/sec is the isotropic free water diffusivity, D is the tissue diffusion tensor, bi and gi are the diffusion-weighting amplitude (in mm2/s) and unit gradient encoding vector, respectively. In this implementation, the use of two non-zero b-values greatly simplifies the parameter space allowing accurate and stable diffusion measures even without spatial constraints and assumptions.

As separate scans were used for each of the diffusion models, all processing procedures through template construction were carried out in parallel, independent processing streams. The FWE-DTI and DTI models were fit in each subject’s native space. Subject specific templates were then created using DTI-TK, as a means to leverage the full tensor information for optimal normalization[4345].


Whole-brain tractography was performed using the fiber assignment by continuous tracking (FACT) algorithm [46] as implemented in the Camino software package ( Tracts were seeded at the center of every voxel with an FA greater than or equal to 0.3. Specific tracts were then reconstructed by constraining viable fibers through the use of targeted inclusion and exclusion ROIs. An FA threshold of 0.3 and a curvature threshold of 60 degrees over 5 mm were used as stopping criteria. Visualization was carried out using TrackVis [47].

The tractography was carried out utilizing the tensor fitting from the FWE-DTI scheme. For each individual subject, the DTI scan was aligned to the native FWE-DTI scan. In this way, the DTI diffusion metrics could be projected onto the tracts reconstructed using FWE-DTI tensors. Using the FWE-DTI tensors instead of DTI tensors ensured a more full reconstruction of the fornix [48]. The metrics of interest for FWE-DTI were the FA, MD, and f-value. Standard DTI analyses were carried out for FA and MD. These metrics were calculated by taking the average value over all voxels, which intersected some portion of the reconstructed tracts.

ROIs were drawn in the template space and subsequently warped back to the native spaces to use as a seed point for deterministic tractography. Native-space tractography reconstructions were performed in brain regions known to be affected by AD [4954], including the corpus callosum (CC), fornix, and cingulum. A single ROI defined on the midsagittal fractional anisotropy (FA) image was used to define the corpus callosum, Fig 1. This was further subdivided into five regions using the scheme proposed by Hofer and Frahm, based on fiber projection regions [55]. These regions were prefrontal (CC-I), premotor and supplementary motor (CC-II), primary motor (CC-III), primary sensory (CC-IV), and parietal, temporal, and visual (CC-V). The fornix was delineated based on intersection with two primary ROIs in the columns and body of the fornix and one of two secondary ROIs in the left and right crux [56], Fig 2. The superior portion of the right and left cingulum bundles were defined by tracts that pass through a pair of ROIs–anterior above the corpus callosum genu and posterior above the corpus callosum splenium [57,58], see Fig 2.

Fig 1. Seed ROIs and example segmentation of the corpus callosum overlaid on an MNI T1-weighted template.

The CC was segmented into the following five regions: CC-I (yellow), CC-II (red), CC-III (blue), CC-IV (orange), and CC-V (green). The middle image shows a streamline reconstruction of the CC with DEC encoding based on the primary eigenvector direction. The rightmost image shows the same reconstruction with color determined by the seed ROI from which the tract originated.

Fig 2. The ROIs used to define the fornix (top row) and superior cingulum (bottom row) in template space.

Fornix tracts were reconstructed if they passed through the columns (green), body (blue) and either the right crux (red) or left crux (yellow). Cingulum tracts were reconstructed if they passed through an anterior ROI (left: yellow, right: purple) and a posterior ROI (left: orange, right: green).

ROI statistical analysis.

The mean value of each diffusion metric was extracted for each ROI for statistical analysis. For the fornix and cingulum bundles, the left and right structures that were separately defined above were merged created a single ROI for each structure. The metrics of interest were FA and MD for DTI as well as FA, MD, and f-value for the FWE-DTI acquisition. Analysis was carried out by fitting a generalized linear model in SPSS 22 (IBM Corp., Armonk, NY), treating the diffusion metrics as dependent variables and the CSF biomarkers and biomarker ratios as predictors, along with age and sex as covariates. In this way, the effect of each biomarker or ratio of markers was analyzed separately on each of the seven tracts and metrics of interest. As a means of controlling for multiple comparisons, a false discovery rate threshold of p ≤ 0 .05 was utilized [59].

Voxel-based analysis.

In addition to the tractography analysis, a voxel-based analysis (VBA) was performed across white matter constrained by white matter mask. This mask was defined as all voxels for which FA ≥ 0.2. Given its importance in AD and susceptibility to early pathology, a separate VBA analysis was also conducted on the hippocampus using a mask based on the Desikan probabilistic structural atlas [6063]. This atlas, which is in Montreal neurological institute (MNI) standard space, was warped to the population atlas space using an affine registration of an accompanying MNI space FA map to the population space FA map.

The VBA analysis utilized nonparametric permutation testing using the randomize function in FSL [64] along with threshold free cluster enhancement [65]. Prior to the VBA, all metric maps were smoothed with a 4mm full width half max Gaussian smoothing kernel. As with the tractography analysis, the effect of age and sex was controlled and the main effect of each biomarker on the diffusion metrics of interest was tested. For each permutation test, 25,000 permutations were carried out. Multiple comparisons were accounted for through the use of a family wise error threshold of p ≤ 0 .05. Once again, this analysis was carried out for the FWE-DTI FA, MD, f-value, and the DTI FA and MD. While all analysis took place in the population template space, these maps were warped to MNI via the inverse warp used for the hippocampus map for standardized reporting and visualization.

Cognitive analysis.

A post-hoc analysis was performed to determine whether white matter impacted by preclinical AD pathology in turn underlies worse cognitive test performance. To test this, we used regression analysis to examine the relationship between white matter microstructure, and MMSE, Trails A, Trails B, RAVLT total, RAVLT delayed, and Wechsler Memory Scale total. As will be reported below, CSF biomarkers of AD were most closely associated with f-value, thus f-value served as the predictor variable in this analysis. To reduce the number of comparisons, we averaged the f-value extracted from all significant clusters and used multiple regression to test the relationship between mean f-value and the cognitive tests. Covariates were age, sex, education, and the time between MR scan and cognitive testing. Correction for multiple comparisons used Bonferroni correction, where there are 6 tests [.05/6], and a corrected p = .008.


Demographics, cognitive function, and CSF

A summary of the cohort demographics is included in Table 1. Participants were non-demented. Mini-Mental Exam scores were largely in the range of normal, with the exception of one participant who scored 25 (3 scored 27, 8 scored 28, 16 scored 29, and the rest scored 30). The one participant who scored 25 on MMSE scored was within normal range on the Rey Auditory Verbal Testing delayed measure and thus remained in the analysis.

Table 1. Summary demographics, cognitive data, and CSF measures from the included participants.

Age was associated with NFL only, as shown in Table 2. One subject (male, APOE4+, FH-) was censured based on poor image quality along with an especially high value on the NFL assay that was more than 5.5 standard deviations above the group mean. This left 69 participants in the remainder of the analyses. Correlations with age in Table 2 were computed after censure of the subject noted above. Several CSF markers were correlated with one another with the strongest correlations being between sAPPα and sAPPβ (ρ = 0.954, P < 0.001) as well as pTau181and tTau (ρ = 0.876, P < 0.001). The APOE4+ group displayed a lower (P < 0.005) mean Aβ42 value (655 ± 168) compared to the APOE4- group (797 ± 192). None of the CSF markers were significantly associated with sex or parental family history of AD.


The diffusion metrics along each tract are presented in Table 3. All DTI results showed a positive correlation between the MD and CSF biomarkers (Table 4). Of the seven ROIs investigated, the ROIs situated in the posterior portions of the corpus callosum (CC-III, CC-IV, and CC-V) were the only ones which showed an association with CSF biomarkers, including pTau181, tTau, and YKL-40 as well as the ratio of each to Aβ42. The most robust results were for the ratios of markers as opposed to individual markers. Table 4 contains the results from tractography for relationships found significant at the uncorrected p = 0.05 threshold. This table also shows the corrected critical value significance threshold level once multiple comparisons are considered. No correlations were significant after false discovery rate correction.

Table 3. Diffusion metrics of tracts.

All values are listed as mean ± standard deviation.

For the FWE-DTI metrics, only the f-value showed a correlation with the CSF biomarkers (Table 5). As with DTI MD, the f-value was positively correlated with the CSF biomarkers. However, in this case the tracts that were affected were primarily the cingulum bundles and CC-I. The FWE-DTI f-value showed a positive relationship with pTau181, pTau181/Aβ42, tTau/Aβ42, YKL-40/Aβ42 and sAPPβ/Aβ42.

Voxel based analysis

The voxel based analysis revealed widespread areas where diffusion metrics were related to pTau181/Aβ42, tTau/ Aβ42 and sAPPβ/Aβ42 in both DTI and FWE-DTI analyses. For FWE-DTI but not DTI, pTau181 was significantly correlated with diffusion measures. As detailed in Tables 6 and 7, associations were largely found in temporal and frontal white matter. Similar to the tractography analysis, the only metrics which showed a significant relation to the CSF biomarkers were DTI MD and FWE-DTI f-value. Likewise, the relationship was positive for all of the clusters identified. An additional summary of the overall extent of significant findings may be found in Table 8.

Table 6. Listing of all significant clusters for which the FWE-DTI f-value was correlated to one of the predictors.

Table 7. Listing of all significant clusters for which the DTI MD was correlated to one of the predictors.

The spatial distribution of clusters for which FWE-DTI f-value or DTI MD were correlated with pTau181/Aβ42 is displayed in Figs 3 and 4, respectively. Scatter plots corresponding to the single largest clusters from Figs 3 and 4 are shown in Figs 5 and 6. For both imaging methods the largest cluster includes the left temporal lobe though with FWE-DTI the contiguous cluster is spread diffusely beyond. Regions where significant associations were found overlapped among comparisons. Tables 9 and 10 show the overlap between the significant cluster areas related to each biomarker or biomarker ratio. As shown in Table 9, with the exception of the clusters due to pTau181 alone, there was substantial overlap between all FWE-DTI clusters with one another; similarly, as shown in Table 10, significant regions of association in the DTI MD analysis also showed substantial overlap. No significant effects were observed for either diffusion method within the hippocampus.

Fig 3. Higher levels of pTau181/Aβ42 were associated with higher FWE-DTI f-value throughout white matter.

The red-yellow color scale above shows the familywise error corrected P-value. The underlay image is a T1w MNI template with 1 mm isotropic resolution.

Fig 4. Higher levels of pTau181/Aβ42 were associated with higher DTI MD primarily in the left and right temporal lobes.

The color scale, underlay, and presented slices are the same as those in Fig 3.

Fig 5. The largest contiguous cluster for which FWE-DTI f-value correlated with pTau181/Aβ42.

All other clusters were masked out of the image. The color scale is the same as that of Fig 3.

Fig 6. The largest contiguous cluster for which DTI MD correlated with pTau181/Aβ42.

All other clusters were masked out of the image. The color scale is the same as that of Fig 3.

Table 9. The percent overlap between the significant finding maps using the FWE-DTI f-value.

Table 10. The percent overlap between the significant finding maps using the DTI MD.

Cognitive function and white matter microstructure

Altered white matter microstructure was not a significant predictor of cognitive test performance. Of the six cognitive test scores assessed, only Trails B showed a modest relationship with mean f-value (b = -.27, p = .03), but this relationship did not survive correction for multiple comparisons.


An estimated 5.4 million Americans have AD. In the absence of effective treatments for the disease, there has been an increased focus on understanding the pathological features that occur in the earliest stages of the disease. Pathological features identified at an early stage may be targets for treatment prior to significant cell loss, in addition to providing utility for identifying candidates for clinical trials. In this study, we tested the extent to which preclinical AD involves alteration to white matter microstructure. White matter alterations have been observed in presymptomatic familial AD [66,67], in addition to being associated with risk factors for sporadic AD [51,6870]. Thus, microstructural white matter changes may be an early and measurable feature of the disease, and new methods for modeling complex diffusion are expected to be sensitive to this early pathology. We found significant associations between markers of AD pathology measured in CSF, and white matter microstructure, especially as indicated by FWE-DTI f-value. In particular, elevated ratios of pTau/Aβ42 and tTau/Aβ42 were robustly associated with higher free water or f-value in frontal and temporal lobe white matter. A novel marker of the amyloid pathway (sAPPβ) also showed a robust association with altered microstructure as shown on FWE-DTI, especially when combined as a ratio with Aβ42. A similar correlation was seen with sAPPα as sAPPα and sAPPβ are themselves highly correlated.

It was previously shown in a smaller group of participants (n = 42) that tau and Aβ42 ratios are associated with MD[10]. Interestingly, the results of the current study also showed that MD derived from standard DTI was associated with higher pTau/Aβ42 in CSF, with peaks of association in temporal lobe white matter. Of note, the current study extends these findings by showing that FWE-DTI appears to demonstrate greater sensitivity to associations between AD pathology and white matter microstructure compared to standard DTI. Further, an analysis of hippocampal gray matter showed no association, suggesting that preclinical AD pathology may be detectable in white matter prior to changes in hippocampal microstructure. Gold et al [49] have previously tested the relationship between CSF markers of AD and both white matter alteration and hippocampal volume. While effects were observed in white matter, no relationship was observed between AD pathology as shown on CSF and hippocampal volume. The results of the current study suggest that indeed, effects on white matter may occur earlier than hippocampal alteration, and further, that this is the case even when diffusion weighted measures are used, which may be more sensitive to subtle change compared to T1-weighted imaging.

The FWE model has been applied previously to a variety of cohorts including older individuals with mild cognitive impairment [7173]. In these instances, the model was applied with the goal of removing confounding CSF effects, as it was here. Some have referred to the f-value as an indicator of atrophy [74,75]. However, the results here indicate that the f-value may be something more than simply the CSF fraction. Parenchymal f-values reported here (~40%) are considerably higher than published reports from a similarly aged cohort (~7–9%) [72]. It is important to consider that the previously mentioned studies use a single b = 1000 s/mm2 diffusion acquisition and heavily regularized fitting scheme [76]. It is likely that the difference in f-value stems from the difference in acquisition schemes. Pasternak and colleagues have noted that using multishell acquisitions results in differences in estimated f-value [16]. While the difference presented here is much greater, so is the deviation in acquisition scheme. We also note that Bruggen et al. observed similar high free water values in their higher b-value multishell study of Alzheimer’s disease[77]. It is well documented that diffusion in tissue at high b-values is decidedly non-Gaussian [78], which may be a significant factor in the elevated f-value.

Non-zero f-values that are measured in tissue distal from CSF may reflect the relative volume of extracellular space in the tissue. In the context of AD, this signal could be due to loss of axons, or loss of myelin in brain white matter. Roher et al have demonstrated substantial alteration in both myelin and axons in familial and sporadic AD [79,80]. The pathology of AD includes hyperphosphorylation of tau protein, resulting in axonal abnormalities and displacement of tau to neuronal cell bodies [81]. Markers in this study that were related to tau (tTau and pTau), in addition to NFL, were strongly associated with white matter microstructural features as shown on FWE-DTI. Given that tau and NFL are components of the axonal cytoskeleton, these results may suggest that the f-value is sensitive to early axonal degeneration. CSF markers and advanced multi-compartment imaging are expected to shed further light on the temporal sequence of axonal and myelin alteration in the course of AD [82].

In this study, we found robust associations between CSF biomarkers reflecting core AD pathology, associated features, and white matter microstructure. Amyloid pathology has been linked with axonal degeneration. Hippocampal neurons cultured in vitro show axonal degeneration due to Aβ42 toxicity, an event that occurs prior to cell body death [83]. Other studies suggest that pathological changes in AD include leakage of amyloid from the extracellular space into the neuron, for example, at the axon hillock [84], causing subsequent axonal pathology. Krstic et al. review evidence that inflammation is involved in increasing neuronal cell vulnerability [85], and indeed, the results of the tractography analysis showed a positive association between MD and YKL-40, a marker of microglial activation—suggesting inflammation—as well as the ratio of YKL-40 to Aβ42. The results did not survive correction for multiple comparisons, but are suggestive. Additional studies are needed to determine the importance of biomarkers of inflammation for predicting development of dementia due to AD.

It is also of interest that higher sAPPβ/Aβ42 showed a widespread association with higher f-value across bilateral temporal and frontal white matter. Soluble Aβ-40 and Aβ-42 are elevated in white matter brain tissue assessed post mortem in AD patients compared to control [86]. APP cleavage by Beta-secretase 1 (BACE1) produces a membrane-bound fragment of APP that when further cleaved by γ-secretase yields several Aβ species including Aβ42 ultimately leading to formation of deposited amyloid plaques [87]. Products of the β-secretase pathway include increases in amyloid-β oligomers, which may be more toxic to neuronal cells than deposited plaques [88]. While CSF sAPPβ is not a direct measure of the oligomeric form of Aβ, the sAPPβ/Aβ42 ratio may reflect both increased proteolytic processing of APP through the amyloidogenic pathway, as well as increased deposition of amyloid, providing a better marker of amyloid pathology than either measure alone. The ratio may also account for inter-individual differences in APP production. To the author’s knowledge, this is the first study showing a link between elevated β-secretase cleavage of APP and in vivo white matter abnormalities as shown on diffusion-weighted imaging in humans.

Our study had a few limitations that deserve mention. The cohort was predominantly female (51 of 69 participants) with little male representation. Additionally, the parameters for the HYDI scan used for fitting the FWE-DTI model differs from the published “optimal” scan for this model [40]. As the DTI and FWE-DTI scans were independent, the acquisitions had different numbers of total images, as well as a different signal to noise ratio per image.


The findings demonstrated that markers of AD pathology are associated with microstructural white matter alteration. In an improvement upon prior DTI studies, we employed a FWE-DTI approach to model complex water diffusion in cerebral white matter. Markers of elevated AD pathology were robustly associated with altered diffusion in bilateral temporal and frontal lobes, regions known to be involved in early stages of AD. These findings add to a growing body of literature indicating that white matter degeneration is likely an early and measurable feature of AD.


The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Department of the Navy, Department of Defense, or the U.S. Government. Research reported in this publication was supported in part by the National Institutes of Health under Grant Award Numbers P50AG033514, R01AG027161, P30HD003352, P50MH100031, and R01AG037639. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Biomarker analyses in this project was supported by the Torsten Söderberg Foundation at the Royal Swedish Academy of Sciences.

Data used in this manuscript are available upon request to the Wisconsin Alzheimer’s Disease Research Center (

Financial Interest Disclosure: Andrew Alexander is part-owner of inseRT MRI, Inc., which was not involved with this study and did not contribute financially to the study. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Author Contributions

  1. Conceptualization: ARH ALA BBB.
  2. Data curation: BBB.
  3. Formal analysis: ARH ML ALA BBB.
  4. Funding acquisition: HZ SCJ ALA BBB.
  5. Investigation: ARH ML ALA BBB.
  6. Methodology: ARH ALA BBB.
  7. Project administration: BBB.
  8. Resources: HZ KB.
  9. Software: ARH.
  10. Supervision: ALA BBB.
  11. Visualization: ARH.
  12. Writing – original draft: ARH ALA BBB.
  13. Writing – review & editing: ARH ML CMC OCO HZ KB MAS SA SCJ ALA BBB.


  1. 1. Gómez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer’s disease. Ann Neurol. 1997;41:17–24. pmid:9005861
  2. 2. Lassmann H, Fischer P, Jellinger K. Synaptic pathology of Alzheimer’s disease. Annals of the New York Academy of Sciences. 1993. p. 59–64.
  3. 3. DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer’s disease: correlation with cognitive severity. Ann Neurol. 1990;27:457–64. pmid:2360787
  4. 4. Perez-Nievas BG, Stein TD, Tai HC, Dols-Icardo O, Scotton TC, Barroeta-Espar I, et al. Dissecting phenotypic traits linked to human resilience to Alzheimer’s pathology. Brain. 2013;136:2510–26. pmid:23824488
  5. 5. Andrade-Moraes CH, Oliveira-Pinto A V, Castro-Fonseca E, da Silva CG, Guimarães DM, Szczupak D, et al. Cell number changes in Alzheimer’s disease relate to dementia, not to plaques and tangles. Brain [Internet]. 2013;136(Pt 12):3738–52. pmid:24136825
  6. 6. Beaulieu C. The basis of anisotropic water diffusion in the nervous system—a technical review. NMR Biomed [Internet]. 2002 [cited 2013 Sep 20];15(7–8):435–55. pmid:12489094
  7. 7. Pfefferbaum A, Sullivan E V., Hedehus M, Lim KO, Adalsteinsson E, Moseley M. Age-related decline in brain white matter anisotropy measured with spatially corrected echo-planar diffusion tensor imaging. Magn Reson Med. 2000;44:259–68. pmid:10918325
  8. 8. Masliah E, Mallory M, Hansen L, DeTeresa R, Terry RD. Quantitative synaptic alterations in the human neocortex during normal aging. Neurology. 1993;43:192–7. pmid:8423884
  9. 9. Ly M, Canu E, Xu G, Oh J, Mclaren DG, Dowling NM, et al. Midlife measurements of white matter microstructure predict subsequent regional white matter atrophy in healthy adults. Hum Brain Mapp. 2014;35:2044–54. pmid:23861348
  10. 10. Bendlin BB, Carlsson CM, Johnson SC, Zetterberg H, Blennow K, Willette A a, et al. CSF T-Tau/Aβ42 predicts white matter microstructure in healthy adults at risk for Alzheimer’s disease. PLoS One [Internet]. 2012 Jan [cited 2014 Nov 6];7(6):e37720. pmid:22701578
  11. 11. Hanyu H, Asano T, Sakurai H, Imon Y, Iwamoto T, Takasaki M, et al. Diffusion-weighted and magnetization transfer imaging of the corpus callosum in Alzheimer’s disease. J Neurol Sci. 1999;167:37–44. pmid:10500260
  12. 12. Canu E, McLaren DG, Fitzgerald ME, Bendlin BB, Zoccatelli G, Alessandrini F, et al. Microstructural diffusion changes are independent of macrostructural volume loss in moderate to severe Alzheimer’s disease. J Alzheimer’s Dis. 2010;19:963–76.
  13. 13. Pasternak O, Westin C-F, Bouix S, Seidman LJ, Goldstein JM, Woo T-UW, et al. Excessive extracellular volume reveals a neurodegenerative pattern in schizophrenia onset. J Neurosci [Internet]. 2012 Nov 28 [cited 2013 Oct 3];32(48):17365–72. pmid:23197727
  14. 14. Alexander AL, Hasan KM, Lazar M, Tsuruda JS, Parker DL. Analysis of Partial Volume Effects in Diffusion-Tensor MRI. 2001;780:770–80.
  15. 15. Metzler-Baddeley C, O’Sullivan MJ, Bells S, Pasternak O, Jones DK. How and how not to correct for CSF-contamination in diffusion MRI. Neuroimage [Internet]. Elsevier Inc.; 2012 Jan 16 [cited 2013 Oct 19];59(2):1394–403. pmid:21924365
  16. 16. Pasternak O, Shenton ME, Westin C-F. Estimation of extracellular volume from regularized multi-shell diffusion MRI. Med Image Comput Comput Assist Interv [Internet]. 2012 Jan;15(Pt 2):305–12. pmid:23286062
  17. 17. Rathi Y, Pasternak O, Savadjiev P, Michailovich O, Bouix S, Kubicki M, et al. Gray matter alterations in early aging: A diffusion magnetic resonance imaging study. Hum Brain Mapp [Internet]. 2013 Dec 31 [cited 2014 Jan 10];00.
  18. 18. Tosto G, Zimmerman ME, Carmichael OT, Brickman AM. Predicting aggressive decline in mild cognitive impairment: the importance of white matter hyperintensities. JAMA Neurol [Internet]. 2014;71:872–7. pmid:24821476
  19. 19. Brinkmalm G, Brinkmalm A, Bourgeois P, Persson R, Hansson O, Portelius E, et al. Soluble amyloid precursor protein α and β in CSF in Alzheimer’s disease. Brain Res [Internet]. 2013 Jun 4 [cited 2014 Nov 30];1513:117–26. pmid:23541617
  20. 20. Sager MA, Hermann B, La Rue A. Middle-aged children of persons with Alzheimer’s disease: APOE genotypes and cognitive function in the Wisconsin Registry for Alzheimer's Prevention. J Geriatr Psychiatry Neurol. 2005;18:245–9. pmid:16306248
  21. 21. Roses AD, Saunders AM. APOE is a major susceptibility gene for Alzheimer’s disease. Curr Opin Biotechnol. 1994;5(6):663–7. pmid:7765750
  22. 22. Wu YC, Alexander AL. Hybrid diffusion imaging. Neuroimage. 2007;36:617–29. pmid:17481920
  23. 23. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA. 2009;302(4):385–93. pmid:19622817
  24. 24. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta;42 in humans. Ann Neurol. 2006;59(3):512–9. pmid:16372280
  25. 25. Buerger K, Ewers M, Pirttil?? T, Zinkowski R, Alafuzoff I, Teipel SJet al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer’s disease. Brain. 2006;129(11):3035–41.
  26. 26. Hampel H, Blennow K, Shaw LM, Hoessler YC, Zetterberg H, Trojanowski JQ. Total and phosphorylated tau protein as biological markers of Alzheimer’s disease. Experimental Gerontology. 2010. p. 30–40.
  27. 27. Lewczuk P, Esselmann H, Bibl M, Beck G, Maler JM, Otto M, et al. Tau protein phosphorylated at threonine 181 in CSF as a neurochemical biomarker in Alzheimer’s disease. J Mol Neurosci. 2004;23(1–2):115–22. pmid:15126697
  28. 28. Koopman K, Le Bastard N, Martin JJ, Nagels G, De Deyn PP, Engelborghs S. Improved discrimination of autopsy-confirmed Alzheimer’s disease (AD) from non-AD dementias using CSF P-tau181P. Neurochem Int. 2009;55(4):214–8. pmid:19524111
  29. 29. Sämgård K, Zetterberg H, Blennow K, Hansson O, Minthon L, Londos E. Cerebrospinal fluid total tau as a marker of Alzheimer’s disease intensity. Int J Geriatr Psychiatry. 2010;25(4):403–10. pmid:19650161
  30. 30. Zetterberg H, Skillback T, Mattsson N, Trojanowski JQ, Portelius E, Shaw LM, et al. Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression. JAMA Neurol. 2015;73(1):1–8.
  31. 31. Mattsson N, Tabatabaei S, Johansson P, Hansson O, Andreasson U, M??nsson JE, et al. Cerebrospinal fluid microglial markers in Alzheimer’s disease: Elevated chitotriosidase activity but lack of diagnostic utility. NeuroMolecular Med. 2011;13(2):151–9. pmid:21567187
  32. 32. Perneczky R, Tsolakidou A, Arnold A, Diehl-Schmid J, Grimmer T, F??rstl H, et al. CSF soluble amyloid precursor proteins in the diagnosis of incipient Alzheimer disease. Neurology. 2011;77(1):35–8. pmid:21700579
  33. 33. Kawas C, Segal J, Stewart WF, Corrada M, Thal LJ. A validation study of the Dementia Questionnaire. Arch Neurol. 1994;51:901–6. pmid:8080390
  34. 34. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984 Jul;34(7):939–44. pmid:6610841
  35. 35. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer’s Dement. 2011 May;7(3):263–9.
  36. 36. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: A practical method for grading the state of patients for the clinician. J Psychiatr Res. 1975;12:189–98. pmid:1202204
  37. 37. Strauss EH, Sherman EMS, Spreen O. A compendium of neuropsychological tests: Adminsitration, norms, and commentary (2nd ed.). Administration Norms And Commentary. 1998.
  38. 38. Cox SG. Neuropsychological assessment (4th edn). Br J Clin Psychol. 2005;44:454.
  39. 39. Reitan RM, Wolfson D. The Halstead-Reitan Neuropsychological Test Battery and REHABIT: A model for integrating evaluation and remediation of cognitive impairment. Cogn Rehabil. 1988;6:10–7.
  40. 40. Hoy AR, Koay CG, Kecskemeti SR, Alexander AL. Optimization of a Free Water Elimination Two-Compartment Model for Diffusion Tensor Imaging. Neuroimage [Internet]. Elsevier B.V.; 2014 Sep [cited 2014 Sep 29];103:323–33. pmid:25271843
  41. 41. Alexander AL, Lee JE, Lazar M, Field AS. Diffusion Tensor Imaging of the Brain. 2007;4(July):316–29. pmid:17599699
  42. 42. Pierpaoli C, Jones DK. Removing CSF Contamination in Brain DT-MRIs by Using a Two-Compartment Tensor Model. International Society for Magnetic Resonance in Medicine Meeting. 2004. p. 1215.
  43. 43. Wang Y, Gupta A, Liu Z, Zhang H, Escolar ML, Gilmore JH, et al. DTI registration in atlas based fiber analysis of infantile Krabbe disease. Neuroimage. 2011;55:1577–86. pmid:21256236
  44. 44. Zhang H, Yushkevich P a, Alexander DC, Gee JC. Deformable registration of diffusion tensor MR images with explicit orientation optimization. Med Image Anal. 2006 Oct;10(5):764–85. pmid:16899392
  45. 45. Zhang H, Yushkevich PA, Rueckert D, Gee JC. Unbiased white matter atlas construction using diffusion tensor images. Med Image Comput Comput Assist Interv. 2007;10:211–8. pmid:18044571
  46. 46. Mori S, Crain B, Chacko V, Van Ziji P. Three-dimensional tracking of axonal projections in the brain by magnetic resonance imaging. Ann Neurol. 1999;45(2):265–9. pmid:9989633
  47. 47. Wang R, Benner T. Diffusion toolkit: a software package for diffusion imaging data processing and tractography. Proc Intl Soc Mag Reson … [Internet]. 2007 [cited 2014 Jul 5];15:3720.
  48. 48. Hoy AR, Kecskemeti SR, Alexander AL. Free water elimination diffusion tractography: A comparison with conventional and fluid-attenuated inversion recovery, diffusion tensor imaging acquisitions. J Magn Reson Imaging. 2015 Apr;1–10.
  49. 49. Gold BT, Zhu Z, Brown CA, Andersen AH, LaDu MJ, Tai L, et al. White matter integrity is associated with cerebrospinal fluid markers of Alzheimer’s disease in normal adults. Neurobiol Aging [Internet]. 2014 Oct [cited 2015 May 8];35(10):2263–71. pmid:24866404
  50. 50. Huang H, Fan X, Weiner M, Martin-Cook K, Xiao G, Davis J, et al. Distinctive disruption patterns of white matter tracts in Alzheimer’s disease with full diffusion tensor characterization. Neurobiol Aging. 2012;33:2029–45. pmid:21872362
  51. 51. Adluru N, Destiche DJ, Lu SY-F, Doran ST, Birdsill AC, Melah KE, et al. White matter microstructure in late middle-age: Effects of apolipoprotein E4 and parental family history of Alzheimer’s disease. NeuroImage Clin [Internet]. 2014;4:730–42. pmid:24936424
  52. 52. Ringman JM, O’Neill J, Geschwind D, Medina L, Apostolova LG, Rodriguez Y, et al. Diffusion tensor imaging in preclinical and presymptomatic carriers of familial Alzheimer’s disease mutations. Brain [Internet]. 2007 Jul [cited 2014 Feb 4];130(Pt 7):1767–76. pmid:17522104
  53. 53. Fellgiebel A, Schermuly I, Gerhard A, Keller I, Albrecht J, Weibrich C, et al. Functional relevant loss of long association fibre tracts integrity in early Alzheimer’s disease. Neuropsychologia. 2008;46:1698–706. pmid:18243252
  54. 54. Takahashi S, Yonezawa H, Takahashi J, Kudo M, Inoue T, Tohgi H. Selective reduction of diffusion anisotropy in white matter of Alzheimer disease brains measured by 3.0 Tesla magnetic resonance imaging. Neurosci Lett [Internet]. 2002;332:45–8. pmid:12377381
  55. 55. Hofer S, Frahm J. Topography of the human corpus callosum revisited—comprehensive fiber tractography using diffusion tensor magnetic resonance imaging. Neuroimage. 2006 Sep;32(3):989–94. pmid:16854598
  56. 56. Okada T, Miki Y, Fushimi Y, Hanakawa T. Diffusion-Tensor Fiber Tractography: Intraindividual Comparison of 3.0-T and 1.5-T MR Imaging 1. Radiology. 2006;238(2):668–78. pmid:16396839
  57. 57. Wakana S, Jiang H, Nagae-Poetscher L, van Zijl P, Mori S. Fiber Tract–based Atlas of Human White Matter Anatomy1. Radiology [Internet]. 2004 [cited 2013 Dec 19];230(1):77–87. pmid:14645885
  58. 58. Pajevic S, Pierpaoli C. Color schemes to represent the orientation of anisotropic tissues from diffusion tensor data: application to white matter fiber tract mapping in the human brain. Magn Reson Med [Internet]. 2000 Jun;43(6):921. pmid:10861892
  59. 59. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J R Stat Soc Ser B [Internet]. 1995;57:289–300.
  60. 60. Makris N, Goldstein JM, Kennedy D, Hodge SM, Caviness VS, Faraone S V., et al. Decreased volume of left and total anterior insular lobule in schizophrenia. Schizophr Res. 2006;83:155–71. pmid:16448806
  61. 61. Frazier J a, Chiu S, Breeze JL, Makris N, Lange N, Kennedy DN, et al. Structural brain magnetic resonance imaging of limbic and thalamic volumes in pediatric bipolar disorder. Am J Psychiatry [Internet]. 2005 Jul;162(7):1256–65. pmid:15994707
  62. 62. Desikan RS, Ségonne F, Fischl B, Quinn BT, Dickerson BC, Blacker D, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage [Internet]. 2006 Jul 1 [cited 2013 Dec 12];31(3):968–80. pmid:16530430
  63. 63. Goldstein JM, Seidman LJ, Makris N, Ahern T, O’Brien LM, Caviness VS, et al. Hypothalamic abnormalities in schizophrenia: sex effects and genetic vulnerability. Biol Psychiatry [Internet]. 2007 Apr 15 [cited 2013 Dec 16];61(8):935–45. pmid:17046727
  64. 64. Winkler AM, Ridgway GR, Webster M a, Smith SM, Nichols TE. Permutation inference for the general linear model. Neuroimage [Internet]. The Authors; 2014 May 15 [cited 2014 Jul 22];92:381–97. pmid:24530839
  65. 65. Smith SM, Nichols TE. Threshold-free cluster enhancement: Addressing problems of smoothing, threshold dependence and localisation in cluster inference. Neuroimage. 2009;44:83–98. pmid:18501637
  66. 66. Li X, Westman E, Ståhlbom AK, Thordardottir S, Almkvist O, Blennow K, et al. White matter changes in familial Alzheimer’s disease. J Intern Med [Internet]. 2015 Jan 31 [cited 2015 May 8];
  67. 67. Ryan N, Keihaninejad S, Shakespeare T, Lehmann M, Crutch S, Malone I, et al. Magnetic resonance imaging evidence for presymptomatic change in thalamus and caudate in familial Alzheimer’s disease. Brain. 2013;136(5):1399–414.
  68. 68. Bendlin B, Ries M, Canu E, Sodhi A. White matter is altered with parental family history of Alzheimer’s disease. Alzheimer’s …. 2010;6(5):394–403.
  69. 69. Lyall DM, Harris SE, Bastin ME, Muñoz Maniega S, Murray C, Lutz MW, et al. Alzheimer’s disease susceptibility genes APOE and TOMM40, and brain white matter integrity in the Lothian Birth Cohort 1936. Neurobiol Aging. 2014;35.
  70. 70. Westlye LT, Reinvang I, Rootwelt H, Espeseth T. Effects of APOE on brain white matter microstructure in healthy adults. Neurology. 2012;79:1961–9. pmid:23100402
  71. 71. Berlot R, Metzler-Baddeley C, Jones DK, O’Sullivan MJ. CSF contamination contributes to apparent microstructural alterations in mild cognitive impairment. Neuroimage [Internet]. The Authors; 2014 Feb 3 [cited 2014 Feb 11];1–9.
  72. 72. Maier-Hein KH, Westin CF, Shenton ME, Weiner MW, Raj A, Thomann P, et al. Widespread white matter degeneration preceding the onset of dementia. Alzheimer’s Dement. 2015;11:485–93.
  73. 73. Metzler-Baddeley C, Jones DK, Steventon J, Westacott L, Aggleton JP, O’Sullivan MJ. Cingulum microstructure predicts cognitive control in older age and mild cognitive impairment. J Neurosci [Internet]. 2012 Dec 5 [cited 2014 Aug 23];32(49):17612–9. pmid:23223284
  74. 74. Metzler-Baddeley C, Hunt S, Jones DK, Leemans A, Aggleton JP, O’Sullivan MJ. Temporal association tracts and the breakdown of episodic memory in mild cognitive impairment. Neurology. 2012;79:2233–40. pmid:23175726
  75. 75. Ray NJ, Metzler-Baddeley C, Khondoker MR, Grothe MJ, Teipel S, Wright P, et al. Cholinergic basal forebrain structure influences the reconfiguration of white matter connections to support residual memory in mild cognitive impairment. J Neurosci. 2015;35:739–47. pmid:25589767
  76. 76. Pasternak O, Sochen N, Gur Y, Intrator N, Assaf Y. Free water elimination and mapping from diffusion MRI. Magn Reson Med [Internet]. 2009 Sep [cited 2013 Sep 23];62(3):717–30. pmid:19623619
  77. 77. van Bruggen T, Zhang H, Pasternak O, Meinzer H-P, Stieltjes B, Fritzsche K. Free-water elimination for assessing microstructural gray matter pathology—with application to Alzheimer’s Disease. International Society for Magnetic Resonance in Medicine Meeting. 22013. p. 790.
  78. 78. Assaf Y, Cohen Y. Non-mono-exponential attenuation of water and N-acetyl aspartate signals due to diffusion in brain tissue. J Magn Reson. 1998;131:69–85. pmid:9533908
  79. 79. Roher AE, Weiss N, Kokjohn TA, Kuo Y, Kalback W, Anthony J, et al. Articles Increased A Peptides and Reduced Cholesterol and Myelin Proteins Characterize White Matter Degeneration in Alzheimer ‘ s Disease †. Biochemistry. 2002;41(37):11080–90. pmid:12220172
  80. 80. Roher AE, Maarouf CL, Malek-ahmadi M, Wilson J, Kokjohn TA, Daugs ID, et al. Subjects harboring presenilin familial Alzheimer ‘ s disease mutations exhibit diverse white matter biochemistry alterations. Am J Neurodegener Dis. 2013;2(3):187–207. pmid:24093083
  81. 81. Larsson EM, Englund E, Sjöbeck M, Lätt J, Brockstedt S. MRI with diffusion tensor imaging post-mortem at 3.0 T in a patient with frontotemporal dementia. Dementia and Geriatric Cognitive Disorders. 2004. p. 316–9. pmid:15178944
  82. 82. Alexander AL, Hurley S a, Samsonov A a, Adluru N, Hosseinbor AP, Mossahebi P, et al. Characterization of cerebral white matter properties using quantitative magnetic resonance imaging stains. Brain Connect [Internet]. 2011 Jan [cited 2014 Aug 12];1(6):423–46. pmid:22432902
  83. 83. Alobuia WM, Xia W, Vohra BPS. Axon degeneration is key component of neuronal death in amyloid-β toxicity. Neurochem Int. 2013;63:782–9. pmid:24083988
  84. 84. Christensen DZ, Huettenrauch M, Mitkovski M, Pradier L, Wirths O. Axonal degeneration in an alzheimer mouse model is PS1 gene dose dependent and linked to intraneuronal aβ accumulation. Front Aging Neurosci. 2014;6.
  85. 85. Krstic D, Knuesel I. Deciphering the mechanism underlying late-onset Alzheimer disease. Nat Rev Neurol [Internet]. 2013;9:25–34. pmid:23183882
  86. 86. Collins-Praino LE, Francis YI, Griffith EY, Wiegman AF, Urbach J, Lawton A, et al. Soluble amyloid beta levels are elevated in the white matter of Alzheimer¿s patients, independent of cortical plaque severity. Acta Neuropathol Commun [Internet]. 2014;2(1):83.
  87. 87. Wolfe MS, Guenette SY. APP at a glance. J Cell Sci [Internet]. 2007;120(18):3157–61.
  88. 88. Lansbury PT. Evolution of amyloid: What normal protein folding may tell us about fibrillogenesis and disease. Proc Natl Acad Sci U S A. 1999;96(March):3342–4.